視網膜靜脈阻塞治療市場規模、佔有率和成長分析（按疾病類型、治療類型、藥物類型、最終用戶和地區分類）－2026-2033年產業預測

預計到 2024 年，視網膜靜脈阻塞治療市場規模將達到 25.9 億美元，到 2025 年將達到 27.6 億美元，到 2033 年將達到 45.3 億美元，在預測期（2026-2033 年）內複合年成長率為 6.4%。

由於視網膜靜脈阻塞（RVO）盛行率不斷上升，以及人口老化導致更多人易患此病，RVO治療市場正經歷顯著成長。 RVO是一種視網膜血管疾病，若不及時治療，可能導致嚴重的視力喪失。該市場提供多種治療方法，旨在改善血流、減輕黃斑部水腫並確保視力喪失，包括藥物治療、雷射治療和手術治療。雖然抗VEGF療法已成為主流，但市場正日益接受新一代治療方法。北美和歐洲憑藉其完善的醫療保健系統和早期技術應用處於領先地位，而亞太地區則因健康意識的提高而迅速發展。對研發的持續投入以及向個人化醫療的轉變，進一步推動了市場擴張，最終改善患者的治療效果。

視網膜靜脈阻塞治療市場促進因素

視網膜靜脈阻塞治療市場的成長受多種關鍵因素影響。全球眼科疾病率的不斷上升以及人口老化推動了對有效治療方法的需求。人們對眼科疾病認知的不斷提高、醫療基礎設施的改善以及技術的創新也在市場發展中發揮關鍵作用。不斷增加的新治療方法研發和核准，以及一系列前景廣闊的在研藥物，正在推動治療效果的提升。病例數的增加、前景廣闊的研究以及創新藥物的出現，共同為視網膜靜脈阻塞市場創造了巨大的成長機會。

限制視網膜靜脈阻塞治療市場的因素

由於缺乏全面的長期臨床證據，視網膜靜脈阻塞治療市場面臨嚴峻的挑戰。亟需對各種治療方法的療效進行全面評估，以確保其與現有治療方法相比的有效性和安全性。數據普遍匱乏可能削弱醫護人員和病人之間的信任，進而影響治療的普及率。因此，進行更嚴謹的臨床試驗和研究至關重要，以檢驗這些治療方法，並提供關於其長期獲益和風險的必要保障，最終有助於臨床實踐中做出更明智的決策。

視網膜靜脈阻塞治療市場趨勢

視網膜靜脈阻塞治療市場正經歷顯著成長，這主要受疾病盛行率不斷上升的推動，尤其是在老年族群。由於老年人更容易患血管疾病，因此對有效治療方法的需求激增。治療方法的進步，例如新型藥物療法和微創手術，提高了患者的治療效果，進一步推動了這一趨勢。此外，人們對眼部健康的日益重視以及高風險族群積極篩檢，也促進了市場的擴張。這些因素共同預示著市場將呈現強勁的成長勢頭，以滿足不斷成長的患者群體的需求。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究
• 監管環境
• 專利分析

全球視網膜靜脈阻塞治療市場規模（依疾病類型及複合年成長率分類）（2026-2033 年）

• 中心性視網膜靜脈阻塞（CRVO）
• 視網膜分支靜脈阻塞（BRVO）

全球視網膜靜脈阻塞治療市場規模（依治療方法和複合年成長率分類）（2026-2033 年）

• 抗 VEGF 藥物
• 皮質類固醇
• 雷射療法

全球視網膜靜脈阻塞治療市場規模（依藥物類型及複合年成長率分類）（2026-2033 年）

• 品牌產品
• 學名藥

全球視網膜靜脈阻塞治療市場規模（依最終使用者分類）及複合年成長率（2026-2033 年）

• 醫院
• 眼科診所
• 門診手術中心（ASC）
• 零售藥房

全球視網膜靜脈阻塞治療市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• AbbVie Inc.（USA）
• Roche（Switzerland）
• Regeneron Pharmaceuticals, Inc.（USA）
• Novartis AG（Switzerland）
• Bayer AG（Germany）
• Alimera Sciences（USA）
• Aerie Pharmaceuticals, Inc.（USA）
• Kodiak Sciences Inc.（USA）
• Chugai Pharmaceutical Co., Ltd.（Japan）
• Taiwan Liposome Company, Ltd.（Taiwan）
• Graybug Vision, Inc.（USA）
• Pfizer Inc.（USA）
• IRIDEX Corporation（USA）
• Lumenis（Israel）
• Nidek Co., Ltd.（Japan）
• Annexin Pharmaceuticals AB（Sweden）
• Outlook Therapeutics, Inc.（USA）
• CalciMedica Inc.（USA）
• F. Hoffmann-La Roche AG（Switzerland）
• Samsung Bioepis（South Korea）

結論與建議

Retinal Vein Occlusion Treatment Market size was valued at USD 2.59 Billion in 2024 and is poised to grow from USD 2.76 Billion in 2025 to USD 4.53 Billion by 2033, growing at a CAGR of 6.4% during the forecast period (2026-2033).

The retinal vein occlusion (RVO) treatment market is experiencing significant growth, spurred by the rising prevalence of RVO and an aging demographic susceptible to this condition. RVO, a vascular disorder of the retina, can lead to severe vision loss if not addressed promptly. The market features diverse treatment modalities, including drug therapies, laser treatments, and surgical options, all aimed at enhancing blood flow, alleviating macular edema, and preventing vision deterioration. With anti-VEGF therapies taking precedence, the acceptance of next-generation treatments is increasing. North America and Europe are at the forefront, propelled by strong healthcare systems and early technology adoption, while the Asia-Pacific region is gaining traction due to enhanced healthcare awareness. Continuous investment in R&D and a shift towards personalized medicine further support market expansion, ultimately aiming to improve patient outcomes.

Top-down and bottom-up approaches were used to estimate and validate the size of the Retinal Vein Occlusion Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Retinal Vein Occlusion Treatment Market Segments Analysis

Global Retinal Vein Occlusion Treatment Market is segmented by Disease Type, Treatment Type, Medication Type, End-user and region. Based on Disease Type, the market is segmented into Central Retinal Vein Occlusion (CRVO) and Branch Retinal Vein Occlusion (BRVO). Based on Treatment Type, the market is segmented into Anti-VEGF, Corticosteroid Drugs and Laser Therapy. Based on Medication Type, the market is segmented into Branded and Generics. Based on End-user, the market is segmented into Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers (ASC) and Retail Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Retinal Vein Occlusion Treatment Market

The growth of the retinal vein occlusion treatment market is influenced by a variety of significant factors. An increase in the prevalence of eye diseases globally, coupled with a rising elderly population, has heightened the demand for effective treatments. Enhanced knowledge of eye disorders, alongside improved healthcare infrastructure and technological innovations, has also played a vital role in market development. The ongoing research and approval of new therapeutic options, supplemented by a strong pipeline of potential treatments, is driving advancements in therapy effectiveness. This convergence of increasing cases, promising research, and innovative medications creates substantial opportunities for growth in the retinal vein occlusion market.

Restraints in the Retinal Vein Occlusion Treatment Market

The Retinal Vein Occlusion Treatment market encounters significant challenges due to the limited availability of comprehensive long-term clinical evidence. There remains a pressing need for thorough evaluation of treatment outcomes associated with various therapeutic approaches to ensure their efficacy and safety in comparison to established methods. This lack of extensive data hinders confidence among healthcare providers and patients, potentially impacting treatment adoption rates. Consequently, more robust clinical trials and research are crucial to validate these treatments and provide the necessary reassurance about their long-term benefits and risks, ultimately facilitating better decision-making in clinical practice.

Market Trends of the Retinal Vein Occlusion Treatment Market

The retinal vein occlusion treatment market is witnessing significant growth driven by the rising prevalence of the condition, especially among the aging population. As older individuals are more susceptible to vascular diseases, the demand for effective therapeutic options is surging. This trend is further fueled by advancements in treatment modalities, including novel pharmacotherapies and minimally invasive procedures, which enhance patient outcomes. Additionally, increasing awareness about eye health and proactive screening in at-risk populations are contributing to market expansion. The convergence of these factors highlights a robust market trajectory focused on addressing the needs of a growing demographic of affected individuals.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies
• Regulatory Landscape
• Patent Analysis

Global Retinal Vein Occlusion Treatment Market Size by Disease Type & CAGR (2026-2033)

• Market Overview
• Central Retinal Vein Occlusion (CRVO)
• Branch Retinal Vein Occlusion (BRVO)

Global Retinal Vein Occlusion Treatment Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Anti-VEGF
• Corticosteroid Drugs
• Laser Therapy

Global Retinal Vein Occlusion Treatment Market Size by Medication Type & CAGR (2026-2033)

• Market Overview
• Branded
• Generics

Global Retinal Vein Occlusion Treatment Market Size by End-user & CAGR (2026-2033)

• Market Overview
• Hospitals
• Ophthalmic Clinics
• Ambulatory Surgical Centers (ASC)
• Retail Pharmacies

Global Retinal Vein Occlusion Treatment Market Size & CAGR (2026-2033)

• North America (Disease Type, Treatment Type, Medication Type, End-user)
  • US
  • Canada
• Europe (Disease Type, Treatment Type, Medication Type, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Disease Type, Treatment Type, Medication Type, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Disease Type, Treatment Type, Medication Type, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Disease Type, Treatment Type, Medication Type, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Regeneron Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alimera Sciences (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aerie Pharmaceuticals, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kodiak Sciences Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chugai Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Taiwan Liposome Company, Ltd. (Taiwan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Graybug Vision, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IRIDEX Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lumenis (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nidek Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Annexin Pharmaceuticals AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Outlook Therapeutics, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• CalciMedica Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Samsung Bioepis (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations